WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, today hosted a Scientific Symposium at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held in Baltimore, MD.The Scientific Symposium showcased Dyno’s approach to applying artificial intelligence to engineering novel adeno-associated virus (AAV) capsids for optimized in vivo delivery. The Symposium, titled “AAV Capsid Design in the Era of AI,” covered Dyno’s approach to solving one of the most difficult challenges of gene therapy: safely and efficiently delivering therapeutic DNA to target organs within a patient’s body.“The present AI revolution in biotech was prefaced by decades of exponential change in the tech industry which catalyzed the personal computer revolution by putting a computer on every desk in every home, then into every pocket and on every wrist. Now the convergence of exponential change in AI, genome sequencing, and DNA synthesis technologies is driving a similar trend, this time with respect to the cost of in vivo gene delivery,” said Eric Kelsic, Ph.D., Founder and Chief Executive Officer of Dyno Therapeutics.“Today gene therapies can cost several millions of dollars per dose,” Kelsic continued. “Dyno is committed to reducing the cost of delivering therapeutic DNA down to zero, which will be key to making the next generation of transformative gene therapies even more affordable. Historical trends suggest that dramatic cost reductions will actually grow the overall gene therapy market, supporting a robust ecosystem of gene therapy developers and eventually enabling billions of patients to benefit from life-changing gene therapies."Using generative AI, Dyno recently increased the efficiency of capsid-mediated in vivo DNA delivery in the eye by 80-fold with the Dyno eCap™ 1 capsid, and to the brain by 100-fold with the Dyno bCap™ 1 capsid. Building on these initial successes, Kelsic shared how Dyno’s AI-powered methods achieved two breakthroughs, in Low-Shot Efficient Accelerated Performance (LEAP), and in the design of synthetic capsid serotypes:Capsids designed with LEAP dramatically outperformed capsids designed by humans without AI-assistance, improving in vivo delivery efficiency and potentially enabling lower manufacturing costs: Dyno developed LEAP technology to efficiently generate capsid sequences with enhanced performance beyond any of the capsids in the training data

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design. Everything life does is controlled by biological sequences: DNA, RNA, and proteins. The capacity to design these sequences can drastically improve outcomes in healthcare and technology. Over the past decade, Dyno has pioneered an AI-powered approach to sequence design, creating some of the first in vivo-validated biologics using generative AI. Recently, Dyno’s proprietary generative AI methods yielded optimized capsid products that allow enhanced in vivo delivery of genetic therapies for Dyno’s partners, including the Dyno eCap™ 1 capsid in the eye and the Dyno bCap™ 1 capsid in the brain. Both have been validated through in vivo studies

Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno's field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.